Treatment of gastroesophageal reflux disease

被引:33
作者
Pettit, M [1 ]
机构
[1] Royal Sussex Cty Hosp, Clin Pharm Unit, Brighton BN2 5BE, E Sussex, England
[2] Univ Brighton, Brighton BN2 5BE, E Sussex, England
来源
PHARMACY WORLD & SCIENCE | 2005年 / 27卷 / 06期
关键词
acid supression; antacids; gastroesophageal reflux disease; GERD; H-2-antihistamines; proton pump inhibitors; prokinetics; sucralfate;
D O I
10.1007/s11096-005-4798-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review brings together information on the treatment of gastroesophageal reflux disease. Published manuscripts were identified from Medline. The articles were then screened for relevance prior to inclusion in the review. Up to 40% of people in Western countries are estimated to regularly experience heartburn, the most characteristic symptom of gastroesophageal reflux disease (GERD). Treatment options available for GERD range from over-the-counter (OTC) antacids to proton pump inhibitors (PPIs) and anti-reflux surgery. Many patients self-medicate with OTC medications such as antacids and low-dose histamine H-2-receptor antagonists (H(2)RA) to relieve episodic or food-related symptoms of GERD, and may not seek medical advice unless symptoms persist or worsen. However, GERD is a chronic disease that frequently affects health-related quality of life and, if not properly managed, the complications of GERD may include erosive oesophagitis (EO), Barrett's oesophagus and adenocarcinoma. Adequate control of acid secretion is key to the successful treatment of the condition. OTC medications provide effective symptom relief to about one quarter of patients suffering from GERD. H2RAs can also provide effective symptomatic relief, particularly in patients with milder GERD, but become less-effective over time. PPIs are the agents of choice for the suppression of gastric acid production and have become the mainstay of therapy for acid-related diseases. PPIs produce significantly faster and more complete symptomatic relief, significantly faster and more complete healing of erosive GERD compared with H2RAs and are also significantly more effective at preventing relapse of EO. There are a number of existing guidelines for the treatment of GERD. Recommendation for initial therapy consist of general measures, such as lifestyle advice in combination with antacids and/or alginates. When general measures fail, the next step is empirical therapy. Two options exist for the expirical treatment of GERD, so-called "step-up" or "step-down" therapy. There are no clear data to support either treatment strategy as a universal approach to all patients; consequently, physicians must always choose the course best suited to the individual patient.
引用
收藏
页码:432 / 435
页数:4
相关论文
共 50 条
  • [31] Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease
    Goirand, Francoise
    Le Ray, Isabelle
    Bardou, Marc
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (09) : 1301 - 1311
  • [32] Some issues of the diagnosis and treatment of gastroesophageal reflux disease
    Avdeev, V. G.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (10) : 120 - 124
  • [33] Itopride in treatment of laryngopharyngeal symptoms of gastroesophageal reflux disease
    Janiak, Maria
    POLISH JOURNAL OF OTOLARYNGOLOGY, 2021, 75 (06): : 38 - 44
  • [34] Surgical treatment of gastroesophageal reflux disease
    Christian A. Gutschow
    Arnulf H. Hölscher
    Langenbeck's Archives of Surgery, 2013, 398 : 661 - 667
  • [35] Endoscopic treatment for gastroesophageal reflux disease
    Timothy T. Nostrant
    MAJ John C. Rabine
    Current Treatment Options in Gastroenterology, 2002, 5 (1) : 51 - 61
  • [36] Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease
    Tietto, Angela
    Faggin, Sofia
    Scarpignato, Carmelo
    Savarino, Edoardo Vincenzo
    Giron, Maria Cecilia
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2025, 21 (01) : 53 - 68
  • [37] Gastroesophageal Reflux Disease and Barrett Esophagus in the Elderly
    Otaki, Fouad
    Iyer, Prasad G.
    CLINICS IN GERIATRIC MEDICINE, 2021, 37 (01) : 17 - 29
  • [38] Evolving pharmacological approaches in gastroesophageal reflux disease
    Altan, Ege
    Blondeau, Kathleen
    Pauwels, Ans
    Farre, Ricard
    Tack, Jan
    EXPERT OPINION ON EMERGING DRUGS, 2012, 17 (03) : 347 - 359
  • [39] Gastroesophageal reflux disease and the relationship with Helicobacter pylori
    Mungan, Zeynel
    Simsek, Binnur Pinarbasi
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2017, 28 : S61 - S67
  • [40] EAES recommendations for the management of gastroesophageal reflux disease
    Fuchs, Karl Hermann
    Babic, Benjamin
    Breithaupt, Wolfram
    Dallemagne, Bernard
    Fingerhut, Abe
    Furnee, Edgar
    Granderath, Frank
    Horvath, Peter
    Kardos, Peter
    Pointner, Rudolph
    Savarino, Edoardo
    Van Herwaarden-Lindeboom, Maud
    Zaninotto, Giovanni
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2014, 28 (06): : 1753 - 1773